General
Preferred name
OBETICHOLIC ACID
Synonyms
6-Ethyl-CDCA ()
6-ECDCA ()
6-Ethylchenodeoxycholic acid ()
INT-747 ()
Ocaliva ()
DSP-1747 ()
P&D ID
PD013001
CAS
459789-99-2
865244-30-0
Tags
natural product
drug
available
Approved by
EMA
FDA
First approval
2016
Drug Status
approved
Drug indication
Primary biliary cholangitis
Insomnia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Obeticholic acid is a semisynthetic bile acid analogue. It acts as a farnesoid X receptor (FXR) agonist. (GtoPdb)
ABSORPTION Peak plasma concentrations (Cmax) of obeticholic acid occurred at a median time (Tmax) of approximately 1.5 hours.; Coadministration with food did not alter the extent of absorption of obeticholic acid.
TOXICITY LD50: not known. ; Overdosage of Obeticholic acid could yield in dose-dependent increase in the incidence of liver-related adverse reactions including portal hypertension, ascites, jaundice and elevation in liver biochemical tests.; Severe Pruritus.
INDICATION Indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Compound Sets
24
AdooQ Bioactive Compound Library
A13866
Cayman Chemical Bioactives
11031
ChEMBL Approved Drugs
CHEMBL566315
ChEMBL Drugs
CHEMBL566315
Concise Guide to Pharmacology 2017/18
3435
Concise Guide to Pharmacology 2019/20
3435
Concise Guide to Pharmacology 2021/22
3435
Concise Guide to Pharmacology 2023/24
3435
Drug Repurposing Hub
DrugBank
DB05990
DrugBank Approved Drugs
DB05990
DrugCentral
5155
DrugCentral Approved Drugs
5155
DrugMAP
DM3Q1SM
DrugMAP Approved Drugs
DM3Q1SM
EU-OPENSCREEN Bioactive Compound Library
EOS100833
Guide to Pharmacology
3435
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL566315
MedChem Express Bioactive Compound Library
HY-12222
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
0462Z4S4OZ
Novartis Chemogenetic Library (NIBR MoA Box)
NURSA ligand set
nursa/index.jsf?doi=10.1621%2FRIWHN49S63
TargetMol Bioactive Compound Library
T1789
External IDs
31
Properties
(calculated by RDKit )
Molecular Weight
420.32
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
0
cLogP
5.11
TPSA
77.76
Fraction CSP3
0.96
Chiral centers
11.0
Largest ring
6.0
QED
0.58
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Autophagy
Metabolic Enzyme/Protease
Target
FXR
Member status
member
MOA
activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation
Farnesoid X Receptor (FXR) Agonists
FXR agonist
Biosynthetic Origin
Terpenoid (Steroid)
Therapeutic Indication
Anticirrhotic
Source data